CT/NG Testing Market Driven by Rise in STI Cases and Accessibility of Portable Testing Platforms in Emerging Economies

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global CT/NG Testing Market- (By Product (Assays & kits, Instruments/Analyzers), By Test Type (Laboratory, Point-of-care testing), By Technology (INAAT, PCR, Immunodiagnostics, Others), By End-User (Diagnostics & Laboratories, Hospitals & Clinics, Others)), Trends, Industry Competition Analysis, Revenue and Forecast To 2034."

According to the latest research by InsightAce Analytic, the Global CT/NG Testing Market is valued at USD 1.8 Bn in 2024, and it is expected to reach USD 4.2 Bn by the year 2034, with a CAGR of 8.4% during a forecast period of 2025-2034.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1984

Chlamydia, a prevalent sexually transmitted infection (STI), is caused by the bacterium Chlamydia trachomatis. Although frequently asymptomatic in women, untreated cases can lead to severe reproductive health complications, including pelvic inflammatory disease (PID), which may result in infertility, ectopic pregnancy, and chronic pelvic pain. Similarly, gonorrhoea, caused by Neisseria gonorrhoeae, is a widespread STI with a notably higher prevalence among young adults. High-risk populations include individuals with multiple sexual partners, those co-infected with other STIs, men who have sex with men (MSM), and individuals engaged in commercial sex work.

The escalating incidence of STIs, combined with increased public awareness and the implementation of supportive governmental initiatives focused on early diagnosis and effective treatment, is significantly driving the expansion of the Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) diagnostics and treatment market.

List of Prominent Players in the CT/NG Testing Market:
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic, Inc. (US),
• Thermo Fisher Scientific Inc. (US),
• Abbott Laboratories (US),
• Bio-Rad Laboratories, Inc. (US),
• Siemens Healthineers AG (Germany),
• Danaher (US),
• Becton,
• Dickinson and Company (US)

Market Dynamics:
Drivers-
The Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) testing market is witnessing substantial growth, primarily fueled by government-led initiatives, funding programs, and strategic support designed to encourage technological innovation. These financial incentives enable organizations to allocate resources toward research and development, expand diagnostic infrastructure, and introduce advanced testing solutions. Enhanced access to such funding allows manufacturers to accelerate innovation in CT/NG diagnostics, contributing to improvements in disease detection, monitoring, and personalized treatment strategies. For example, during National STD Awareness Week in April 2022, Chiricahua Community Health Centers, Inc. (CCHCI) collaborated with The Body Agency Collective (TBAC) and Visby Medical, Inc. to strengthen capabilities in sexually transmitted infection (STI) diagnostics and treatment.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2025-04

Challenges:
The cost structure associated with Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) testing is significantly impacted by fluctuating expenditures related to critical reagents, specialized diagnostic instruments, and vendor-specific setup charges. Moreover, additional operational costs-including equipment servicing, insurance, laboratory management, and administrative overhead such as facility rental-further contribute to the overall financial burden. As a result, high-capacity institutions, including major hospitals and centralized reference laboratories, are more likely to have the financial capability to adopt and maintain advanced diagnostic platforms. In contrast, smaller laboratories, private medical practices, and independent healthcare providers often encounter financial limitations, which can restrict their ability to invest in and utilize high-cost diagnostic technologies. The cost of CT/NG diagnostic kits and equipment can vary between USD 2,000 and USD 80,000, representing a significant barrier to widespread adoption and potentially restraining the growth of the CT/NG diagnostics market.

Regional Trends:
The Asia-Pacific region is projected to register the highest compound annual growth rate (CAGR) during the forecast period, supported by the rising incidence of sexually transmitted infections (STIs) across developing economies. Growth in this region is further bolstered by the implementation of targeted awareness campaigns, increased public education initiatives, and robust governmental support aimed at improving public health infrastructure and expanding access to STI diagnostic services. These combined efforts are expected to significantly enhance the uptake of CT/NG testing solutions throughout the Asia-Pacific region.

Recent Developments:
• In May 2022, - Abbott said that its Alinity m STI Assay had been approved by the FDA. The test finds and separates four common sexually transmitted diseases (STIs) at the same time. If STIs aren't addressed, they can cause serious health problems, like an increased chance of getting certain cancers or being unable to have children.
• In Oct 2022, Bio-Rad released two Exact Diagnostics molecular controls. The CT/NG Positive Run Control was designed for molecular tests of Chlamydia trachomatis and N. gonorrhoeae. The company said the STI Negative Run Control monitored the absence of Chlamydia trachomatis and Neisseria gonorrhoeae in molecular assays and could be used to detect laboratory testing errors, including contamination events while controlling for sample adequacy.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1984

Segmentation of CT/NG Testing Market-
By Product-
• Assays & kits
• Instruments/Analyzers
By Test Type-
• Laboratory,
• Point-of-care testing
By Technology-
• INAAT,
• PCR,
• Immunodiagnostics
• Others
By End-User-
• Diagnostics & Laboratories
• Hospitals & Clinics
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Read Overview Report- https://www.insightaceanalytic.com/report/ctng-testing-market/1984

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.